explore -WSS

explore

author：fashion 2025-10-01 21:35:41 - browse：197

Adam's take main illustration — Molly Ferguson/STAT

Hello! Some takes and thoughts on Gilead’s Trodelvy troubles, Elevation Oncology’s surprising rise, and Kura Oncology’s “wall-crossing” stock sale.

Gilead needs Arcellx more than ever

The clinical trial setback for Trodelvy in non-small cell lung cancer reported by Gilead Sciences on Monday was another dose of bad news for the company’s oncology business. Strategically, does it make sense for Gilead to invest even more in antibody-drug conjugates like Trodelvy, where its lackluster profile and increased competition overall makes winning seem unlikely? Or, should Gilead double down on its Kite division and CAR-T cell therapy — the type of cancer treatments where it truly excels?

If the answers to those questions are no and yes (I lean that way), then Gilead’s current partnership with Arcellx, which is developing a BCMA-targeted CAR-T therapy for multiple myeloma, becomes a lot more important.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Roche’s Alnylam deal shows drug firms interested in heart drugs

explore

WSS

Pennsylvania man bitten on the head by bear during attack in his garage

'Investigate these claims': UFO transparency at center of House hearing

Device maker Teleflex to acquire urology company for $600M

Tuberculosis patients need more than just free medication

Former reverend arrested for allegedly killing 8

Former reverend arrested for allegedly killing 8

knowledge

explore

Gilead needs Arcellx more than ever

entertainment

What does generative AI mean for health care? We asked experts

STAT Report: Patient voices and perspectives

After affirmative action ruling, medical educators look to 'holistic review'

Sage considers ways to reduce costs following FDA rejection

FDA approval of Sarepta Duchenne genetic therapy gives me hope

UHS says company favors patients whose insurance pays more

Jerome Adams on the need for new antivirals for Covid

New Alzheimer's drugs heat up race for early detection blood tests

Walensky prepares to leave CDC — and Congress — behind

Paxlovid rebound happens. Why and to whom are still a mystery

hotspot

A new crop of companies is reshaping the health data economy

Roche’s Alnylam deal shows drug firms interested in heart drugs

With heat waves through August, officials warn of health risks

Search called off for baby washed away in Pennsylvania flash flood

Flash flood warnings continue for parts of Missouri, Illinois

The battle over 'scope creep' and who gets to be called 'doctor'

Wikipedia

knowledge

explore

hotspot